The IL-1 decoy receptor rilonacept could be a therapeutic alternative for patients with familial Mediterranean fever who are resistant to, or intolerant of, treatment with colchicine. In a randomized, double-blind, single-participant alternating treatment study, the median number of attacks per month during 3-month courses of rilonacept 2.2 mg/kg was 0.77, compared with 2.00 during 3-month courses of placebo (median difference −1.74, 95% CI −3.4 to −0.1) in the 12 patients who completed the study. The duration of attacks did not differ between courses of placebo and rilonacept, however, and injection site reactions were more frequent with rilonacept.
ORIGINAL RESEARCH PAPER
Hashkes, P. J. et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann. Intern. Med. 157, 533–541 (2012)
Rights and permissions
About this article
Cite this article
Rilonacept for familial Mediterranean fever?. Nat Rev Rheumatol 8, 692 (2012). https://doi.org/10.1038/nrrheum.2012.195
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.195